Treating C. difficile: The Downside to Current Approaches
NOV 10, 2017 | CONTAGION® EDITORIAL STAFF
Stuart Johnson, MD, infectious disease clinician in the Medicine/ID department at Loyola University Medical Center, discusses the disadvantages to some of the current approaches used to treat C. difficile.
Interview Transcript (modified slightly for readability):
“Traditionally, Clostridium difficile infection has been treated with antibiotics that are active against the bacteria; it’s a big of an irony that the disease is typically precipitated by antibiotic treatment meant for, say, urinary tract infection, pneumonia, et. cetera. But the treatment certainly involves classically, antibiotics directed against the organism.
The downside of this, of course, would be that the antibiotics are what got the patient into the situation they’re in, and the treatment, although usually effective for controlling the infection, also have a collateral damage to the flora, the gut that perpetuates this recurrence, if you will.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512